Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.47 |
| ▸ | UTS2R | Q9UKP6 | 12/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3898507 | 1.00 | CACNA2D1 (0.47) | CACNA2D1UTS2RCCR2ALOX5LMNA | |
| SCHEMBL5915001 | 0.89 | CACNA2D1 (0.38) | CACNA2D1UTS2RCCR2ALOX5LMNA | |
| SCHEMBL5915051 | 0.89 | CACNA2D1 (0.38) | CACNA2D1UTS2RCCR2ALOX5LMNA | |
| SCHEMBL5914989 | 0.89 | CACNA2D1 (0.38) | CACNA2D1UTS2RCCR2ALOX5LMNA | |
| SCHEMBL5915024 | 0.88 | LMNA (0.39) | CACNA2D1UTS2RCCR2ALOX5LMNA | |
| SCHEMBL6271962 | 0.88 | LMNA (0.39) | CACNA2D1UTS2RCCR2ALOX5LMNA | |
| SCHEMBL5915026 | 0.88 | LMNA (0.39) | CACNA2D1UTS2RCCR2ALOX5LMNA | |
| SCHEMBL5915053 | 0.85 | KDM4E (0.38) | CACNA2D1CCR2ALOX5LMNATP53 | |
| SCHEMBL5915005 | 0.85 | KDM4E (0.38) | CACNA2D1CCR2ALOX5LMNATP53 | |
| SCHEMBL5915082 | 0.85 | CACNA2D1 (0.45) | CACNA2D1UTS2RCCR2ALOX5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009019719-A2 | PROCESS FOR THE PREPARATION OF 3-ARYLOXY-3-ARYLPROPANAMINES | IND-SWIFT LABORATORIES LIMITED (IN) | 2009-02-12 | — | — | WO | disclosed |
| US-20060167278-A1 | Propanolamine derivatives, process for preparation of 3-n-methylamino-1-(2-thienyl)-1-propanols and process for preparation of propanolamine derivatives | MITSUBISHI RAYON CO. LTD. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1506965-A1 | PROPANOLAMINE DERIVATIVES, PROCESS FOR PREPARATION OF 3-N-METHYLAMINO-1-(2-THIENYL)-1-PROPANOLS AND PROCESS FOR PREPARATION OF PROPANOLAMINE DERIVATIVES | Mitsubishi Rayon Co., Ltd. (JP) | 2005-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167278-A1 | Propanolamine derivatives, process for preparation of 3-n-methylamino-1-(2-thienyl)-1-propanols and process for preparation of propanolamine derivatives | ADRA1A, ADRB1, ADRA1D | CACNA2D1 2433/4885UTS2R 1082/4885CCR2 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.